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Background: Hirsutanol A is a novel sesquiterpene compound purified from fungus Chondrostereum sp. in Sarcophyton
tortuosum. Our previous studies had demonstrated that hirsutanol A exhibited potent cytotoxic effect on many kinds of
cancer cell lines. In the current study, the antitumor activity of hirsutanol A and its molecular mechanisms were
investigated.
Methods: Hirsutanol A induced growth inhibition and apoptotic cell death of human colon cancer SW620 cells and
human breast cancer MDA-MB-231cells were determined using MTT assay and flow cytometry assay, respectively. The
effect of hirsutanol A on intrinsic ROS level and change in mitochondrial membrane potential (△ψm) of different cell lines
were also measured by flow cytometry assay. The function of JNK was compromised by JNK siRNA or JNK inhibitor
SP600125. The expression of cytochrome c, p-JNK, p-c-Jun after treatment with hirsutanol A were detected by Western blot
analysis. Finally, the in vivo anti-tumor effect of hirsutanol A was examined in human cancer cell SW620 xenograft model.
Results: The results showed that hirsutanol A significantly induced apoptosis, mitochondrial-independent increase of
Reactive Oxygen Species (ROS) level, change of mitochondrial membrane potential, release of cytochrome c in human
cancer cells. Preventing increase of ROS level using the potent antioxidant N-acetyl-L-cysteine (NAC) markedly decreased
hirsutanol A-induced apoptosis. In addition, JNK signaling pathway was activated by hirsutanol A through elevating ROS
level. Blockade of JNK signaling pathway by JNK specific inhibitor SP600125 enhanced apoptosis and hirsutanol
A-induced ROS accumulation. Also, hirsutanol A exhibited antitumor activity in human cancer cell SW620 xenograft
model.
Conclusion: These data suggested that hirsutanol A inhibited tumor growth through triggering ROS production and
apoptosis.
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Figure 1 The chemical structure of Hirsutanol A.
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ROS (Reactive Oxygen Species) is a collective term for oxy-
gen derived species, including superoxide anion radical O2
.-,
hydroxyl radicals .OH etc. [1]. The basic level of intracellular
ROS is considered to be important to promote cell prolifera-
tion and differentiation. However, excessive amounts of
ROS can contribute to carcinogenesis and cancer progres-
sion [2,3]. Therefore, maintaining ROS homeostasis is cru-
cial for normal cell growth and survival [4]. Compared to
normal cells, cancer cells with increasing intrinsic ROS are
more vulnerable to damage by further ROS insults induced
by exogenous agents [5]. Manipulating ROS levels by redox
modulation is one way to selectively kill cancer cells sparing
normal cells. Hence, the redox system is considered as a
new target for anticancer drugs [6,7].
Apoptosis is a highly regulated and organized cell death
process, which controls the development and homeostasis
of multicellular organisms [8]. Death receptor signaling
pathway and mitochondrial pathway are two major path-
ways mediating apoptosis triggered by different apoptotic
stimuli [9,10]. Alterations in the cellular ROS status have
been proven to play an important role in apoptotic cell
death [11]. Excessive ROS will attack lipids and proteins of
mitochondria membrance, leading to severe and irreversible
oxidative damage, dysfunction of mitochondria, and release
of cytochrome c, which in turn activates the caspase-3 initi-
ating mitochondria / cytochrome c –mediated apoptosis
[12,13].
C-Jun NH2-terminal kinases (JNKs) are strongly activated
by oxidative stress, which can induce apoptosis or regulate
cellular ROS level by activating its downstream molecule c-
Jun [14]. C-Jun is fisrt phosphorylated by JNK and then
translocates to the nucleus for further regulating the tran-
scription of target genes including some pro-apoptotic or
antiapoptotic proteins such as Bax and Bcl-2 and some
redox proteins such as NOX, SOD [15,16].
Hirsutanol A is a novel sesquiterpene compound purified
from fungus Chondrostereum sp. in Sarcophyton tortuosum
[17]. Our previous studies showed that Hirsutanol A exerted
potent cytotoxic effect on many kinds of human cancer cell
lines [18,19]. In this study, we examined the molecular
mechanism of Hirsutanol A-induced apoptosis and its anti-
tumor activity in human cancer cell SW620 xenograft
model. We demonstrated that Hirsutanol A could induce
apoptosis in SW620 and MDA-MB-231 cells and signifi-
cantly inhibit tumor growth in vivo. Futhermore, we found
that hirsutanol A could elevate intrinsic ROS level, and acti-




Fetal bovine serum and RPMI-1640 media were pur-
chased from GibcoW (New York, USA). 3-(4,5-dime-thylthiazol-2- thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT), CM-H2DCF-DA, Dimethyl sulfoxide (DMSO),
N-acetyl-L-cysteine (NAC) were obtained from Sigma-
Aldrich (St. Louis, USA). 10-Hydroxycamplothecin
(HCPT) was purchased from Huangshi Feiyun Pharma-
ceutical Co., Ltd (Hubei, China). Antibodies against
Hsp60, JNK, p-JNK, chemiluminescence reagent were
acquired from Cell Signaling Technology (Danvers, MA,
USA). Antibodies against GAPDH, Caspase-3, PARP,
Cyto-c, p-c-Jun and anti-mouse Ig-G-horseradish perox-
idase, anti-rabbit Ig-G-horseradish peroxidase were from
Santa Cruz Biotechnology (Santa Cruz, USA). The c-Jun
antibody was purchased from Boster Biotech (Wuhan,
Hubei, China). Cell lysis was from Upstate Biotech Co
(New York, USA). Hirsutanol A, a sesquiterpene com-
pound, was isolated from fungus Chondrostereum sp. in
Sarcophyton tortuosum, and initially dissolved in 100%
DMSO at 100nM and stored at −20°C. Its structure is
shown in Figure 1.
Cell lines and cell culture
Human colon cancer cell line SW620 and human breast
cancer cell line MDA-MB-231 were cultured in RPMI-
1640 media supplemented with 10% heat-inactivated
fetal bovine serum, penicillin (50U/ml) and streptomycin
(50 μg/ml) at 37°C in 5% (v/v) CO2. All experiments
were carried out with cells in logarithmic growth phase.
MTT assay
SW620 and MDA-MB-231 cells were first seeded in 96-
well plate at a density of 8,000 cells per well, then trea-
ted with different concentrations of hirsutanol A for
indicated times or pre-incubated with 1mmol/L antioxi-
dant NAC for 1 h, then cultivated for 72 h at 37°C.
10 μL of 5 mg/mL MTT was added into each well before
the termination of experiment. The plates were incu-
bated at 37°C, 5% (v/v) CO2 for 4 h. After complete re-
moval of the medium, 100 μL of DMSO was added into
each well to dissolve the insoluble purple formazan
product. Absorbance values were obtained with a test
wavelength of 570 nm. The rates of cell growth inhib-
ition were calculated based on the absorbance values.
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method: Inhibitory rate = (1-the average OD value of
treatment group/ the average OD value of the control
group) × 100% [20].
Annexin V/Propidium Idodide (PI) double-staining assay
Annexin V/PI staining was performed using the Annexin
V-fluorescein isothiocyanate apoptosis detection kit.
Cells (3.0 × 105 per mL) were seeded into six-well plate
with 2 mL in each well, then treated with different con-
centrations of hirsutanol A for 72 h or pretreated with
1mmol/L NAC or 10 μmol/L SP600125 followed by hir-
sutanol A for 72 h. Both floating and attached cells were
collected, washed with ice-cold PBS twice, then incu-
bated at room temperature in the presence of media
binding reagent and Annexin V-FITC for 15min in the
dark. After washing with PBS, the cells were re-
suspended in ice-cold 1 × binding buffer and treated
with 10 μL propidium iodide (30 μg/ml) on ice in the
dark. Apoptosis was quantified by flow cytometry (Bec-
ton Dickinson) at the wavelength of 488 nm immediately
and analyzed by the Cell-Quest software [21].
Flow cytometry assay and measurement of ROS
Cells were diluted to 3.0 × 105 per mL, seeded into six-well
plate with 2 mL in each well. SW620 cells and MDA-MB-
231 cells were treated with hirsutanol A for indicated times
or treated with various concentrations of hirsutanol A for
24 h, or pre-incubated with 1 mmol/L NAC or 1 μmol/L
SP600125 followed by hirsutanol A for 24 h, then incubated
with 1 μmol/L (final concentration) CM-H2DCF-DA or
DHE florescent dye in dark for 1 h at 37°C. After washing
twice with ice cold PBS, cells were centrifuged and re-
suspended in PBS. The level of intracellular ROS was
detected by flow cytometry with FACS Calibur system and
CellQuestPro analysis software [22].
Immunoblotting analysis
Cells were seeded into six-well plate, treated with hirsu-
tanol A for indicated times or pre-incubated with NAC
for 1 h followed by hirsutanol A for 24 h. Cells were har-
vested and washed twice with PBS and lysed in lysis buf-
fer. The cell lysates were clarified by centrifugation at
12,000 g for 10 min at 4°C and the protein concentration
was determined using the Bio-Rad protein assay (Bio-
Rad laboratories). SDS-PAGE sample buffer was added
to cell lysates. Then the cell lysates were heated at 100°C
for 5 min, and cell lysates containing 20–40 μg protein
was loaded in each well of 8% (w/v) and 15% (w/v) SDS-
PAGE gel. Resolved proteins were electrophoretically
transferred to PVDF membrane, which was incubated
sequentially with primary antibody and horseradish per-
oxidase–conjugated second antibody. After washing, the
bound antibody complex was detected using an ECLchemiluminescence reagent and XAR film (Kodak) as
described by the manufactures [23,24].
siRNA transfection
The target sequence for JNK-specific siRNA was 50-
AAAAAGAAUGUCCUAC CUUCU-30, and control
siRNA (no silencing) were synthesized by GenChem Co.
One day before transfection, cells were plated in six-well
plates with antibiotic-free growth medium at a density of
1.5 × 105 cells per well. When cells grew to a confluency
of 30-50% on the second day, transfection was per-
formed by using Opti-MEM media, lipofectamine 2000
and JNK siRNA according to manufacturer’s recommen-
dations. The final concentration of JNK siRNA was 100
nM. After 6 h, the Opti-MEM media was replaced with
the antibiotic free growth media and cells were treated
with 20 μmol/L hirsutanol A for 3 h.Cells transfected
with lipofectamine 2000 were used as control [25].
Mitochondrial /cytosol fractionation
The isolation of cell mitochondrial and cytosolic frac-
tions was performed using mitochondria/cytosol frac-
tionation kit according to the following protocol. Cells
previously treated with 20 μmol/L hirsutanol A for 24 h
were harvested at ~850 × g for 2 min and 800 μl of mito-
chondria isolation reagent A and 10 μl of mitochondria
isolation reagent B were added. After 5 min incubation
on ice, 800 μl of mitochondria isolation reagent C was
added and the mixture was centrifuged at 700 × g for 10
min at 4°C. The supernatant was further centrifuged at
12,000 × g for 15 min at 4°C in order to pellet the crude
mitochondria. 500 μl mitochondria isolation reagent C
was then added to the pellet before the final centrifuga-
tion at 12,000 × g for 5 min at 4°C. The resulting mito-
chondrial pellet and cytosol fraction were lysed by lysis
buffer before further processing [26].In vivo antitumor studies
BALB/c nude mice (4 to 6 week-old) were obtained from
Guangzhou University of Chinese Medicine. All manipu-
lation was done under sterile conditions. The procedures
involving mice and their care were in accordance with
National Institutes of Health Guide for the care and use
of Laboratory Animals and with the United Kingdom
Coordinating Committee on Cancer Research. Tumor
xenografts were established by injecting 1 × 106 SW620
cells into the subcutaneous tissue in both flank of nude
mice. Mice were randomly divided into six groups and
each group contained 6 mice. Treatment was initiated
on day 6 after inoculation, by which time the volume of
the tumor had reached approximately 50mm3. Different
concentration of hirsutanol A (20 mg/kg/d, 10 mg/kg/d,
5 mg/kg/d), DMSO, 0.9% (w/v) NaCl Saline (N.S.) and
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assigned group. Tumor volumes and body weight of the
mice were observed. Tumor volumes were calculated by
the formula: 0.5 × a × b2 in millimeters, where a is the
length and b is the width. On day 28 after administra-
tion, the mice were sacrificed. The tumor tissues were
excised and weighed. Tumor growth inhibition was
determined as the ratio of the average tumor weight of
the treated group (T) to the average tumor weight of the
control group (C) [27].Statistical analysis
Data were analyzed by student’s t test with SPSS 11.0
analysis software, and results were considered statisti-
cally significant at p < 0.05. Results are presents as mean
and standard deviation (±SD).Figure 2 Growth inhibition and apoptosis induced by hirsutanol A in
different concentrations of Hirsutnol A for 72 h, 48 h, 24 h respectively. The
with various concentrations of hirsutanol A for 72 h, AnnexinV/PI analysis w
from the SW620 and MDA-MB-231 cells after treatment with indicated con
Caspase-3 were detected by immunoblotting assay (C). Results are presentResults
Hirsutanol A inhibited proliferation and induced
apoptosis in SW620 and MDA-MB-231 cells
Using MTT assay, we found that hirsutanol A inhibited
cell proliferation in a dose- and time- dependent man-
ner. The half-maximal inhibitory concentration (IC50)
were 1.90 μmol/L, 6.16 μmol/L, 13.43 μmol/L for
SW620 cells and 10.48 μmol/L, 18.01 μmol/L, 35.67
μmol/L for MDA-MB-231 cells after treatment with hir-
sutanol A for 72, 48, 24 h respectively (Figure 2A). In-
hibition of cell growth could be the consequences of the
induction of apoptosis, necrosis and cell growth arrest
[28]. Thereby, we investigated whether hirsutanol A could
induce apoptosis in SW620 and MDA-MB-231 cells.
Phosphatidyl serine translocation to the cell surface is an
important indicator of early apoptosis [29]. AnnexinV-
fluorescein isothiocyanate/propidium iodide staining assaySW620 and MDA-MB-231 cancer cells. Cells were treated with
inhibitory rate was detemined by MTT assay (A). Cells were treated
ere used to detect the cell apoptosis (B). Proteins were harvested
centrations of hirsutanol A for 48 h. Cleavage fraction of PARP and
ed as means ± SD from 3 independent experiments.
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percentages of AnnexinV-positive cells were 2.8%, 12.1%,
45.0%, 65.6% in SW620 and 2.6%, 10.0%, 22.7%, 30.6% in
MDA-MB-231 after treatment with various concentra-
tions of hirsutanol A for 72 h. These data indicated that
hirsutanol A could induce apoptosis in a dose-dependent
manner (Figure 2B). Furthermore, with Western blot ana-
lysis we found that pro-caspase-3 was cleaved to form a
17KDa fragment and PARP was cleaved into an 89KD
fragment (Figure 2C). These results suggest that hirsuta-
nol A significantly induced apoptosis in SW620 and
MDA-MB-231 cells.
Hirsutanol A induced mitochondrial-independent
accumulation of intrinsic ROS
Previous studies had confirmed that hirsutanol A could
induce autophagical cell death by causing an accumula-
tion of ROS level in human hepatocellular carcinoma
cells [18]. As reactive oxygen species mainly include
hydrogen peroxide H2O2 and superoxide anion radical
O2
.-, in the present study, the effect of hirsutanol A on
cellular superoxide and hydrogen peroxide level was
measured in SW620 cells and MDA-MB-231 cells. The
level of superoxide and hydrogen peroxide in cancer
cells were analyzed by flow cytometry using DHE and
CM-H2DCF-DA as fluorescent probe [30,31]. There was
no significant change in DHE fluorescence after treat-
ment with hirsutanol A for 3h but a remarkable increase
of CM-H2DCF-DA fluorescence in a dose-dependentFigure 3 Hirsutanol A induced mitochondrial-independent accumulat
stained with DHE for 1 h after exposure to hirsutanol A for 3 h. The cellular
means ± SD from 3 independent experiments. (** < 0.05 versus *) (A). SW62
hirsutanol A for 24 h or with 20 μmol/L and 30 μmol/L hirsutanol A for ind
Results are presented as means ± SD from 3 independent experiments. (**
20 μmol/L hirsutanol A for 5 h, and then stained with CM-H2DCF-DA for 1fashion (Figure 3A and 3B), suggesting that the ROS
induced by hirsutanol A were mainly hydrogen peroxide
instead of superoxide. Since accumulation of ROS was
mainly caused by the increase of mitochondrial respira-
tory chain production and decrease of capability for
scavenging ROS by the redox system, we thereby investi-
gated whether hirsutanol A-induced increase of ROS
was related to mitochondria. C6F cells, a clone of rho-0
cells (mitochondrial respiration defective) derived from
HL-60 cells and parental HL-60, were used to detect
whether hirsutanol A-induced accumulation of ROS
production was mitochondrial respiratory chain related.
Results showed that both the parental HL-60 and roh-0
cells (C6F) were highly sensitive to hirsutanol A. C2, C8
cells (rho-0 cells) and parental Raji cells also showed
similar effect after treatment with hirsutanol A, which
suggested that the accumulation of ROS production
were mitochondrial respiratory chain independent
(Figure 3C).
Preventing ROS accumulation by antioxidant agent NAC
reduced hirsutanol A-induced apoptosis
Excessive ROS could lead to mitochondrial membrane
damage, the release of cytochrome c from mitochondrial
and cell apoptosis. The evidences of apoptosis and up-
regulation of ROS levels in cells treated with hirsutanol
A prompted us to investigate whether up-regulation of
ROS would resulted in apoptosis. The increase of ROS
levels in hirsutanol A-treated cancer cells was preventedion of intrinsic ROS in SW620 and MDA-MB-231 cells. Cells were
O2 level was monitored by flow cytometry. Results are presented as
0 and MDA-MB-231 cells were treated with various concentrations of
icated time respectively, and then stained with CM-H2DCF-DA for 1.
< 0.01 versus *) (B). Raji, HL60, C2, C8 and C6F cells were treated with
hour. The cellular H2O2 level was monitored by flow cytometry (C).
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ition was analyzed using MTT assay and AnnexinV-
positive cells were detected by Annexin V/PI double
staining assay (Figure 4A to 4C). The results showed
that hirsutanol A-induced AnnexinV-positive cells and
growth inhibition were significantly reduced. In addition,
prevention of ROS accumulation could inhibit the PARP
cleavage in hirsutanol A-treated cells (Figure 4D). These
data suggested that accumulation of ROS mediated hir-
sutanol A-induced apoptosis.
Hirsutanol A activated mitochondria/cytochrome c
signaling pathway
To further study whether hirsutanol A induced apop-
tosis via activation of mitochondria/cytochrome c signal-
ing pathway, we examined the change of mitochondrial
membrane potential and the release of cytochrome c
from mitochondria. Mitochondrial membrane potentialFigure 4 Preventing ROS accumulation by antioxidant agent NAC red
NAC for 1h, then treated with hirsutanol A for 3h. The cellular H2O2 level w
from 3 independent experiments. (** < 0.05 versus *; *** < 0.01 versus *) (A
with various concentrations of hirsutanol A for 72h. The growth inhibition
were pre-incubated with 1mmol/L NAC for 1h, then treated with various c
AnnexinV/PI analysis (C).Cells were pre-incubated with 1mmol/L NAC for 1h
fraction of PARP was detected by immunoblotting assay (D).was elevated after treatment with various concentrations
of hirsutanol A (Figure 5A). The expression of cyto-
chrome c in mitochondria was down-regulated, whereas
cytosolic cytochrome c was increased after treatment
with hirsutanol A for 24 h (Figure 5B). These data
revealed that hirsutanol A induced apoptosis through acti-
vation of mitochondria/cytochrome c signaling pathway.
Hirsutanol A activated JNK signaling pathway and
blockade of JNK signal pathway increased ROS level and
cell apoptosis
It has been reported that ROS can modulate several sig-
naling pathways including JNK, Akt, NF-κB etc. [32,33].
Therefore, we explored the effect of increased ROS by
hirsutanol A on JNK signaling pathway. JNK and c-Jun
phosphorylation were significantly elevated in SW620
cells after treatment with hirsutanol A for 24 h
(Figure 6A). However, this activation of JNK could beuced hirsutanol A-induced apoptosis. Cells were pre-incubated with
as monitored by flow cytometry. Results are presented as means ± SD
). Cells were pre-incubated with 1mmol/L NAC for 1h , then treated
in SW620 and MDA-MB-231 cells were detected by MTT assay (B). Cells
oncentrations of hirsutanol A for 48h. Cell apoptosis was detected by
, then treated with 20μmol/L hirsutanol A for 24h. The cleavage
Figure 5 Hirsutanol A activated mitochondria/cytochrome c signaling pathway. Cells were exposed to various concentrations of hirsutanol
A for 3h. The △ψm was determined by flow cytometry. Results are presented as means ± SD from 3 independent experiments. (** < 0.01 versus *)
(A). Cells were first treated with 20μmol/L hirsutanol A for 24h. Proteins obtained from cytosolic and mitochondria fractions were detected by
immunoblotting assay (B).
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suggested that JNK may be a downstream target of ex-
cessive ROS. In order to further explore the contribution
of JNK signaling pathway to hirsutanol A-induced ROS
accumulation, JNK signaling pathway was blocked using
the small molecule JNK inhibitor SP600125 [34]. The
percentage of AnnexinV- positive cells was 35.6% when
cells were treated with hirsutanol A only, , whereas in
parallel treatment in combination with SP600125, the
percentage of AnnexinV-positive cells was 48.3%, sug-
gesting that blocking of JNK signaling pathway pro-
moted hirsutanol A-induced apoptosis (Figure 6C). The
results also revealed that inhibiting JNK signaling path-
way enhanced the growth inhibition effect induced by
hirsutanol A (Figure 6D).
We further investigated the effect of activation of JNK
signaling pathway on cellular ROS levels. Cellular ROS
levels were remarkably increased in SW620 cells by JNK
inhibitor SP600125 or JNK-siRNA (Figure 6E).These
results suggested that activation of JNK could be one re-
sponse to oxidant stress which protects cells from deathvia regulation of ROS in a negative feedback manner. It
was not a classic mechanism involved in apoptosis.
In vivo antitumor effect of hirsutanol A on human colon
cancer cell SW620 xenografts
To detect the antitumor activity of hirsutanol A in vivo,
human colon cancer SW620 xenografts were established.
The results showed that hirsutanol A at 10 mg/kg /d po-
tently inhibited tumor growth (Figure 7).
Discussion
Hirsutanol A is a novel sesquiterpene compound puri-
fied from fungus Chondrostereum sp. in Sarcophyton tor-
tuosum. Our previous studies had demonstrated that
hirsutanol A exhibited potent cytotoxic effect on some
human cancer cell lines. In addition, we also confirmed
that hirsutanol A could induce autophagical cell death
by causing accumulation of ROS level in human hepato-
cellular carcinoma cells [18]. ROS inducer as an antican-
cer drug has received a lot of attention due to its
selective effect on cancer cells but sparing normal cells
Figure 6 Hirsutanol A activated JNK signaling pathway through elevating of ROS production and blockage of JNK signal pathway
increased apoptosis and elevated ROS level induced by hirsutanol A. SW620 cells were treated with 20 μmol/L hirsutanol A for indicated
times or various concentrations of hirsutanol A for 24 h. The expression of p-JNK and p-c-Jun were detected by immunoblotting assay (A). SW620
cells were pre-incubated with NAC for 1 h, then treated with 20 μmol/L hirsutanol A for 24 h. The expression of p-JNK was determined by
immunoblotting assay (B). SW620 cells were pre-incubated with SP600125 for 1 h , then treated with 20 μmol/L hirsutanol A for 72 h. Cell growth
inhibition were detected by MTT assay (C). SW620 cells were pre-incubated with SP600125 for 1 h , then treated with 20 μmol/L hirsutanol A for
48 h. Cell apoptosis was detected by AnnexinV/PI analysis (D). SW620 cells were pre-incubated with SP600125 for 1 h or transfected with
JNK- siRNA to block JNK signaling pathway, then treated with 20 μmol/L hirsutanol A for 3 h. Cellular ROS level was monitored by flow
cytometry. Results are presented as means ± SD from 3 independent experiments. (** < 0.05 versus *; *** < 0.01 versus *) (E).
Figure 7 In vivo anti-tumor effect of hirsutanol A on human
colon cancer cells SW620 xenografts. Cells were injected
subcutaneously in BALB/C nude mice. After 6 days of implantment,
BALB/C nude mice were treated with 5% DMSO, NS, hirsutanol A
(10 mg/kg) or HPTC (4 mg/kg) for four weeks. Tumor sizes were
measured twice weekly until the termination of the experiment (A).
Mice were sacrificed on day 21.
Yang et al. Journal of Translational Medicine 2013, 11:32 Page 8 of 10
http://www.translational-medicine.com/content/11/1/32[35]. To date, there are some ROS inducers targeting
ROS generating system or ROS scavenging system
[7,36]. However, most of them cannot enter clinical trials
because of the high toxicity or poor bioavailability. Here,
we reported that hirsutanol A could significant induce
cell growth inhibition and apoptosis, elevate the level of
ROS in both SW620 and MDA-MB-231 cells and sup-
press tumor growth in SW620 xenografts (Figures 2, 3
and 7). Some evidences supported that ROS as a potent
oxidant agent could damage mitochondrial membrane
to result in mitochondrial membrane potential disorder
and release of cytochrome c from mitochondria which
could further activate caspase-3, leading to mitochon-
dria/cytochrome c –mediated apoptosis [37]. We had
examined the mitochondrial membrane potential and
the expression of cytochrome c in mitochondria and
cytosol. The results showed that hirsutanol A could trig-
ger the dysfunction of mitochondrial membrane poten-
tial and release of cytochrome c from mitochondria
(Figure 5). Furthermore, we evaluated whether hirsuta-
nol A-induced growth inhibition and apoptosis were
evoked by accumulation of ROS. After treatment with
NAC, a potent antioxidant agent that could prevent hir-
sutanol A-induced ROS accumulation [38], we found
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decreased (Figure 4). As our data has clearly demon-
strated that hirsutanol A could elevate intrinsic ROS
level, and activate mitochondria/cytochrome c signaliing
pathway to trigger apoptosis, further studies are required
to elucidate if the release of cytochrome c is due to the
elevated ROS induced by hirsutanol A.
ROS, which serves as a second messenger, can modulate
several signaling pathways including JNK, Akt, NF-κB etc.
[32,33]. In this study, we showed that hirsutanol A enhanced
the phosphorylation levels of JNK and c-Jun dose-and time-
dependently in SW620 cells (Figure 6A). Moreover, preven-
tion of hirsutanol A-induced ROS accumulation by NAC
could reverse the phosphorylation of JNK and c-Jun
(Figure 6B). These data indicated that hirsutanol A-induced
production of ROS activated JNK signaling pathway. JNK
signaling pathway is involved in both stress-induced and
chemotherapeutical drugs-induced apoptosis. However, in-
hibition of JNK signaling pathway by a special inhibitor
SP600125 promoted the hirsutanol A-induced cell growth
inhibition and apoptosis. Mass evidences verified that JNK
signaling pathway is responsible for regulation of ROS level
by activating c-Jun, a transcription factor, which further reg-
ulates the transcription of some target genes involved in
redox such as NOX and SOD, etc. [39,40]. In our studies,
we found that blockade of JNK signaling pathway by
SP600125 and siRNA-JNK could significantly enhance hir-
sutanol A-induced ROS production, suggesting that hirsuta-
nol A-induced activation of JNK signaling pathway
regulated ROS level in a negative feedback manner. These
evidences point us in the direction that treatment with hir-
sutanol A in combination with inhibitor of JNK may pro-
duce synergistic effect.
Conclusion
In summary, hirsutanol A is a ROS generating agent
which exerts anticancer effect via up-regulation of ROS
level and activation of mitochondria/cytochrome c sig-
naling pathway. Moreover, hirsutanol A could activate
JNK signaling pathway. Activation of JNK signaling
pathway did not mediate apoptosis; however, it could
regulate ROS level in a negative feedback fashion which
protects cells against oxidant stress induced cell death.
Our results revealed that hirsutanol A may be a promis-
ing lead compound in future anticancer treatments.
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